Suzhou Saipu Biotechnology

About Suzhou Saipu Biotechnology

Established in 2018 within the Suzhou Industrial Park, Suzhou Saipu Biotechnology Co., Ltd. (CellPro) operates as a manufacturer and solutions provider of high-end biomedical consumables. The company has established itself within China's life sciences sector, focusing on the development, production, and sale of specialized plasticware.

CellPro's business model is centered on manufacturing and supplying a wide array of products while also offering customized services. Revenue is generated through the sale of its extensive product portfolio and by providing bespoke solutions, from mold design and manufacturing to large-scale production for biomedical firms. The company serves a global clientele across more than 50 countries in sectors such as molecular diagnostics, biopharmaceuticals, cell and gene therapy, and clinical medicine.

The firm's product lineup includes over 900 SKUs across categories like liquid handling, cell culture, molecular detection, sample storage, and immunoassay. Specific products include pipette tips, centrifuge tubes, PCR plates, petri dishes, and blood collection tubes. CellPro differentiates itself through its integrated capabilities, housing a high-precision mold R&D center and advanced production facilities. The company operates over 140 automated production lines within a 50,000 m² facility, which includes extensive ISO Class 7 and 8 cleanrooms. This vertical integration allows for control over the entire process from R&D and mold design to final production and biological verification.

Since its inception, CellPro has achieved significant milestones, securing over 80 patents and receiving recognition as a National High-tech Enterprise and a potential "unicorn" in China. The company is venture capital-backed, with investors including CICC Capital and YuanBio Venture Capital. Positioned within the burgeoning biotech hub of Suzhou, which aims to become a world-class 'Pharma Valley', CellPro is contributing to the region's rapid growth in the life sciences industry.